Domestic Animal Endocrinology
Volume 38, Issue 2 , Pages 95-102 , February 2010

Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats

  • M. Hoenig

      Affiliations

    • Department of Veterinary Clinical Medicine and College of Veterinary Medicine, University of Illinois, Urbana, IL, USA
    • Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
    • Corresponding Author InformationCorresponding author at: College of Veterinary Medicine, University of Illinois, 1008 W Hazelwood Drive, SAC 13 Urbana, IL 61802, USA. Tel.: +1 217 244 5044; fax: +1 217 244 1475.
    • ,
  • E.T. Jordan

      Affiliations

    • Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
    • ,
  • D.C. Ferguson

      Affiliations

    • Department of Veterinary Biosciences, College of Veterinary Medicine, University of Illinois, Urbana, IL, USA
    • ,
  • F. de Vries

      Affiliations

    • Boehringer-Ingelheim Vetmedica GmbH, Ingelheim, Germany

Received 20 May 2009 ,Revised 6 August 2009 ,Accepted 9 August 2009.

References 

  1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003; 26:S5-S20.
  2. Woerle HJ, Pimenta WP, Meyer C. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1C values. Arch Intern Med. 2004;164:1627–1632
  3. Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes?. Diabetes Care. 2009;32:100–105
  4. Sinha R, Fisch G, Teague B, Tamborlane WV, Bruna Banyas , Allen K, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802–810
  5. http://www.endotext.org/protocols
  6. Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab. 2008;93:4231–4237
  7. Knopf CF, Cresto JC, Dujovne IL, Ramos O, de Majo SF. Oral glucose tolerance test in 100 normal children. Acta Diabetol Lat. 1977;14:95–103
  8. http://www.diabetes.org/about-diabetes.jsp
  9. Kaneko JJ. Carbohydrate metabolism and its diseases. In:  Kaneko JJ editors. Clinical Biochemistry of Domestic Animals. 4th ed.. San Diego, CA: Academic Press; 1989;p. 44–85
  10. Church DB. A comparison of intravenous and oral glucose tolerance tests in the dog. Res Vet Sci. 1980;29:353–356
  11. Irvine AJ, Butterwick R, Watson T, Millward D, Morgan LM. Determination of insulin sensitivity in the dog: an assessment of three methods. J Nutr. 2002;132:1706S–1708S
  12. Lechin F, Coll-García E, van der Dijs B, Bentolila A, Peña F, Rivas C. The effects of dopaminergic blocking agents on the glucose tolerance test in 6 humans and 6 dogs. Cell Mol Life Sci. 1979;35:876–877
  13. Kreyman B, Ghatei MA, Williams G, Bloom SR. Glucagon like peptide-1 7-36: A physiological incretin in man. Lancet. 1987;2:1300–1304
  14. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992;22:283–291
  15. Theodorakis MJ. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol. 2006;290:E550–E559
  16. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med. 2000;17:713–719
  17. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut. 1996;38:916–919
  18. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on ß-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380–386
  19. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastic inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76:912–917
  20. Orskov C, Wettergren A, Holst JJ. Biological effects andmetabolic effects of glucagon-like peptide-1 7-36 amideand glucagon-like peptide-1 7-36 in healthy subjects are indistinguishable. Diabetes. 1993;42:658–661
  21. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetesmellitus. N Engl J Med. 1992;326:1316–1322
  22. Flint A, Raben A, Astrup A, Holst RR. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–520
  23. Hoenig M, Thomaseth K, Brandao J, Waldron M, Ferguson DC. Assessment and mathematical modeling of glucose turnover and insulin sensitivity in lean and obese cats. Domest Anim Endocrinol. 2006;31:573–589
  24. Hoenig M, Thomaseth K, Waldron M, Ferguson DC. Fatty acid turnover, substrate oxidation, and heat production in lean and obese cats during the euglycemic hyperinsulinemic clamp. Domest Anim Endocrinol. 2007;32:329–338
  25. Hoenig M, Thomaseth K, Waldron M, Ferguson DC. Insulin sensitivity, fat distribution and adipocytokine response to different diets in lean, and obese cats before and after weight loss. Am J Physiol. 2007;292:R227–R234
  26. Nelson RW, Himsel CA, Feldman EC, Bottoms GD. Glucose tolerance and insulin response in normal-weight and obese cats. Am J Vet Res. 1990;51:1357–1362
  27. Hoenig M, Ferguson DC. Impairment of glucose tolerance in hyperthyroid cats. J Endocrinol. 1989;121:249–251
  28. Anderson TW, Darling DA. Asymptotic theory of certain “goodness-of-fit” criteria based on stochastic processes. Ann Math Stat. 1952;23:193–212
  29. Shapiro SS, Wilk MB. An analysis of variance test for normality (complex samples). Biometrika. 1965;52:591–611
  30. Callaham M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. JAMA. 2002;287:2847–2850
  31. Steiger JH. Review of SYSTAT, the system for statistics, by Leland Wilkinson. Multivariat Behavior Res. 1988;23:133–139
  32. Arfsten DP, Still KR, Wilfong ER, Johnson EW, McInturf SM, Eggers JS, et al. Two-generation reproductive toxicity study of implanted depleted uranium (DU) in CD rats. J Toxicol Environ Health A. 2009;72:410–427
  33. Mandel R. Software reviews: Resampling stats publisher. Soc Sci Comput Rev. 1997;15:305–308
  34. Drapeau C, Ma H, Yang Z, Tang L, Hoffman RM, Schaeffer DJ. The stem cell mobilizer (R) does not promote tumor growth in an orthotopic model of human breast cancer. Anticancer Res. 2009;29:443–447
  35. Marsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–1470
  36. Cardenas ML. Comparative biochemistry of glucokinase. In:  Matschinsky FM,  Magnuson MA editor. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Basel, Switzerland: Karger; 2004;p. 31–41
  37. Tanaka A, Inoue A, Takeguchi A, Washizu T, Bonkobara M, Arai T. Comparison of expression of glucokinase gene and activities of enzymes related to glucose metabolism in livers between dog and cat. Vet Res Commun. 2005;29:477–485
  38. Hosokawah H, Hosokawa YA, Leahy J. Upregulated hexokinase activity in isolated islets from diabetic 90% pancreatectomized rats. Diabetes. 1995;44:1328–1333
  39. Cockburn BN, Ostrega DM, Sturis J, Kubstrup C, Polonsky KS, Bell GI. Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes. Diabetes. 1997;46:1434–1439
  40. Washizu T, Tanaka A, Sako T, Washizu M, Arai T. Comparison of the activities of enzymes related to glycolysis and gluconeogenesis in the liver of dogs and cats. Res Vet Sci. 1999;67:205–206
  41. Lin HC, Elashoff JD, Gu Y-G, Meyer JH. Effect of meal volume on gastric emptying. Neurogastroenterol Motil. 1992;4:157–163
  42. Noakes TD, Rehrer NJ, Maughan R. The importance of volume in regulating gastric emptying. Med Sci Sports. 1991;23:307–313
  43. Bernstein RS, Thornton JC, Yang MU, Wang J, Redmond AM, Pierson RN, et al. Prediction of the resting metabolic rate in obese patients. Am J Clin Nutr. 1983;37:595–602
  44. Boer JO, de , Es AJH, van , Raaij JMA, van , et al. Energy requirements and energy expenditure of lean and overweight women, measured by indirect calorimetry. Am J Clin Nutr. 1987;46:13–21
  45. Molnar D, Schutz Y. The effect of obesity, age, puberty and gender on resting metabolic rate in children and adolescents. Eur J Pediatrics. 1997;156:376–381
  46. Hoenig M, Rand J. Feline obesity. In:  August JR editors. Consultations in Feline Internal Medicine. Philadelphia: WB Saunders; 2006;p. 175–182
  47. Nauck MA, El Ouaghlidi A, Gabrys B, Hucking K, Holst JJ, Deacon CF, et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept. 2004;122:209–217
  48. Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med. 1993;10:44–49
  49. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706–2713
  50. le Roux C, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780–785
  51. Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–1716
  52. Lugari R, Dei Cas A, Ugolotti D, Barilli C, Camellini G, Ganzerla C, et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res. 2004;36:111–115
  53. Rask E, Olsson T, Söderberg S, Johnson O, Seckl J, Holst JJ, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24:1640–1645
  54. Kley S, Hoenig M, Glushka J, Jin ES, Burgess SC, Waldron M, et al. The impact of obesity, sex, and diet on hepatic glucose production in cats. Am J Physiol Regul Integr Comp Physiol. 2009;296:R936–R943
  55. Hoenig M, Alexander S, Holson J, Ferguson DC. Influence of glucose dosage on interpretation of intravenous glucose tolerance tests in lean and obese cats. J Vet Intern Med. 2002;16:529–532
  56. Sirinek KR, Pace WG, Crockett SE, O’Dorisio TM, Mazzaferri EL, Cataland S. Insulin-induced attenuation of glucose-stimulated gastric inhibitory polypeptide secretion. Am J Surg. 1978;135:151–155
  57. http://www.millipore.com/immunodetection/id3/elisa

PII: S0739-7240(09)00097-6

doi: 10.1016/j.domaniend.2009.08.004

Domestic Animal Endocrinology
Volume 38, Issue 2 , Pages 95-102 , February 2010

Article Tools

* Image Usage & Resolution